TP53 and neoplasm: Additionally, the transcription factor SOX2 has been found to promote lineage plasticity and antiandrogen resistance in prostate cancer cases lacking TP53 and RB1 tumor suppressor genes, contributing to the development of more aggressive and enzalutamide resistant phenotypes (Mu et al., 2017).